Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-585, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer (mCRPC) who have received 2 or more prior lines of therapy. The study consists of 2 parts, a …

Florida Cancer Specialists
 (5.4 away) Contact site
  • 0 views
  • 26 May, 2021
  • +2 other locations
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

To evaluate the safety and tolerability of ERAS-601. To determine the ERAS-601 Maximum Tolerated Dose (MTD) and/or recommended dose (RD) as a monotherapy and in combination with a MEK inhibitor. To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with a MEK inhibitor.

Sarah Cannon Research Institute (Florida Cancer Specialists)
 (4.8 away) Contact site
  • 0 views
  • 31 Jul, 2021
  • +5 other locations
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy of TAS3681 at the MTD/recommended dose (Expansion Phase).

Sarah Cannon Research Institute
 (5.4 away) Contact site
  • 0 views
  • 16 May, 2021
  • +10 other locations
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim …

measurable disease
fluorouracil
investigational treatment
docetaxel
gemcitabine
GSK Investigational Site
 (5.4 away) Contact site
  • 0 views
  • 26 Jan, 2021
  • +29 other locations
Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The initial course of MK-5890 monotherapy or MK-5890 plus pembrolizumab combination therapy will be for up to 35 administrations (approximately 2 …

mk-3475
antineoplastic
paclitaxel
pembrolizumab
lung cancer
Florida Cancer Specialists ( Site 0002)
 (4.8 away) Contact site
  • 283 views
  • 02 Aug, 2021
  • +11 other locations
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with relapsed/refractory hematologic malignancies. The purpose of this study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be used in subsequent development of PRT1419.

measurable disease
leukapheresis
cancer
ejection fraction
platelet count
Florida Cancer Specialists
 (4.8 away) Contact site
  • 0 views
  • 16 Apr, 2021
  • +4 other locations
A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.

Sarasota Clinical Research
 (7.1 away) Contact site
  • 0 views
  • 26 Jun, 2021
  • +8 other locations
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.

Sarasota Retina Institute
 (7.1 away) Contact site
  • 0 views
  • 27 Jun, 2021
  • +7 other locations
Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers

This study is a first-in-human, Phase 1, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of IGM-8444 as a single agent and in combination with a chemotherapy-based regimen in patients with relapsed and/or refractory solid tumors.

measurable disease
growth factor
targeted therapy
bevacizumab
platelet count
Florida Cancer Specialists
 (4.8 away) Contact site
  • 17 views
  • 29 Mar, 2021
  • +5 other locations
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

hodgkin's disease
gilbert's syndrome
large b-cell lymphoma
indolent lymphoma
refractory non-hodgkin's lymphoma
Florida Cancer Specialists
 (4.8 away) Contact site
  • 0 views
  • 31 Jul, 2021
  • +4 other locations